Skip to content

Real world study on adjuvant treatment of non-small cell lung cancer with commonly used anti-cancer traditional Chinese medicine injection

Real world study on adjuvant treatment of non-small cell lung cancer with commonly used anti-cancer traditional Chinese medicine injection

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2100005212
Enrollment
Unknown
Registered
2021-03-18
Start date
2021-03-20
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Interventions

Sponsors

Beijing Hospital of Traditional Chinese Medicined
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients with primary lung cancer hospitalized in the oncology department of Beijing Traditional Chinese medicine hospital from January 1, 2016 to December 31, 2018 according to the standardized diagnosis and treatment guidelines; (2) The patients were treated with platinum containing double drug chemotherapy for more than 2 cycles; (3) Traditional Chinese medicine injection and Kang'ai injection were used simultaneously in chemotherapy.

Exclusion criteria

Exclusion criteria: At the same time, there are other primary malignant tumors; Lung tumor metastases from other sites to the lung; Pathological diagnosis was small cell lung cancer.

Design outcomes

Primary

MeasureTime frame
Tumor markers;

Secondary

MeasureTime frame
Overall survival;TCM Syndrome;KPS;

Countries

China

Contacts

Public ContactChanghe Sun

Beijing University of Chinese Medicine

2579159653@qq.com+86 13051527579

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026